BIOTECH ASSISTANT / FIELD NOTES

Hansoh licenses ex-Greater-China HS-20118 rights to Avere alongside proposed NextCure merger

Company / institutional announcement · Hansoh Pharma

Source published: 2026-07-14 · Event / reporting date: 2026-07-14

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Hansoh granted Avere exclusive development, manufacturing, and commercialization rights to HS-20118, also called AVR-001, outside Greater China. The oral cyclic IL-23R antagonist agreement includes $120 million in upfront payments, up to $2.18 billion in milestones, and royalties. Avere also announced a proposed NextCure merger. Conditional milestone value and a signed merger agreement do not represent realized payments or closing.

Why it may matter

Clarifies regional rights and company structure; shared asset names should not be counted as separate medicines or completed transactions.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oral cyclic peptides

Related updates

2026-11-02AJMC

Enlicitide reports address durability and baseline cardiovascular risk

Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.

Oral cyclic peptides Ask AI ↗

2026-10-30Aurinia / SEC

Aurinia reports $232.4 million in nine-month LUPKYNIS net product sales

Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.

Oral cyclic peptides Ask AI ↗

2026-10-29Acta Pharmaceutica Sinica B

New review maps evidence standards for orally active peptides

A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.

Oral cyclic peptides Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗